Authors
Latest:
Moving the Dial on CLL Management: Sequencing Strategies and Unmet NeedsBefore addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.
Latest:
Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial CarcinomaBradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.
Latest:
Dr Carthon on Darolutamide Plus ADT in mHSPCBradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
Latest:
The Rapidly Changing Landscape in RCC Therapy: What Future Research May HoldThe poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.
Latest:
Dr. Somer on the Impact of the IMbrave150 Trial on the HCC ParadigmBradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.
Latest:
Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.
Latest:
Heterogeneity of Endometrial CancerExperts in gynecologic cancer discuss the heterogeneity of endometrial cancer..
Latest:
Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.
Latest:
Biomarker Testing and Multidisciplinary Approaches in ECKey opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.
Latest:
The Future of Endometrial Cancer TreatmentExperts give insight on what they are looking forward to in the endometrial cancer space.
Latest:
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCCBradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Dr. Stein Discusses Changes to the NCCN Guidelines in MPNsBrady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).
Latest:
Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic CancerBrandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.
Latest:
Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic CancerBrandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.
Latest:
Cota-Watson Effort Aims at Optimal Cost Margins as Well as Improved CareInvestigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.
Latest:
BTK Inhibitors Show Continued Promise in CLLBrian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.
Latest:
In-Office Dispensing Is Better ValueWith increased competition, the challenge in-office dispensing practices now face is to prove the value of what they do.
Latest:
Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLCBrandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).
Latest:
Dr. Inman on Immunotherapy Combinations in Bladder CancerBrant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
